PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers.

Abstract S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.
PMID
Related Publications

GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.

Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.

Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.

Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.

Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.

Authors

Mayor MeshTerms
Keywords
Journal Title advances in anatomic pathology
Publication Year Start




PMID- 28398953
OWN - NLM
STAT- MEDLINE
DA  - 20170411
DCOM- 20170418
LR  - 20170418
IS  - 1533-4031 (Electronic)
IS  - 1072-4109 (Linking)
VI  - 24
IP  - 3
DP  - 2017 May
TI  - S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison
      With Novel and Traditional Urothelial Immunohistochemical Markers.
PG  - 151-160
LID - 10.1097/PAP.0000000000000150 [doi]
AB  - S100P, or placental S100, is a member of a large family of S100 proteins and
      considered to be a promising immunohistochemical marker to support urothelial
      differentiation. This review synthesizes published data regarding the expression 
      of S100P in urothelial carcinoma across histological grade and variant patterns, 
      and in other malignancies, in an effort to summarize the state of understanding
      of this marker and evaluate its potential. We provide also a broad comparison of 
      S100P with other contemporary and traditional urothelial markers and outline the 
      potential utility of S100P in various diagnostically challenging scenarios. Taken
      in context, we recommend that to provide immunohistochemical support for
      consideration of urothelial differentiation, S100P may be included in a panel of 
      markers (due to its high sensitivity), with better established (GATA3) and more
      specific (uroplakin 2) markers, for comparison with corresponding markers of
      other primary sites under consideration, depending on the clinical context. We
      emphasize that the overall most appropriate panel for any given case depends on
      the differential diagnosis engendered by the morphology encountered, and the
      constellation of clinical findings. As always with immunohistochemical panels,
      expected positive and negative markers for each diagnostic consideration should
      be included. Finally, since as of date there are no optimally sensitive or
      specific markers of urothelial differentiation, all final diagnoses relying on
      immunohistochemical support should be made in the appropriate clinical and
      histological context.
FAU - Suryavanshi, Moushumi
AU  - Suryavanshi M
AD  - *Department of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Research 
      Institute, Delhi, India daggerDepartment of Pathological Anatomy, San Carlos
      Hospital Clinic/Complutense University, Madrid, Spain section signDepartment of
      Diagnostics and Public Health, University of Verona, Verona, Italy double
      daggerDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical
      Center, Los Angeles, CA parallelDepartments of Pathology and Urology, VCU School 
      of Medicine, Richmond, VA paragraph signDepartment of Pathology and Laboratory
      Medicine, University of Tennessee Health Science Center, Memphis, TN.
FAU - Sanz-Ortega, Julian
AU  - Sanz-Ortega J
FAU - Sirohi, Deepika
AU  - Sirohi D
FAU - Divatia, Mukul K
AU  - Divatia MK
FAU - Ohe, Chisato
AU  - Ohe C
FAU - Zampini, Claudia
AU  - Zampini C
FAU - Luthringer, Daniel
AU  - Luthringer D
FAU - Smith, Steven C
AU  - Smith SC
FAU - Amin, Mahul B
AU  - Amin MB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Anat Pathol
JT  - Advances in anatomic pathology
JID - 9435676
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Transitional Cell/metabolism/*pathology
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Urinary Bladder Neoplasms/diagnosis/metabolism/*pathology
MH  - Urologic Neoplasms/diagnosis/metabolism/*pathology
MH  - Urothelium/*pathology
EDAT- 2017/04/12 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/12 06:00
AID - 10.1097/PAP.0000000000000150 [doi]
AID - 00125480-201705000-00004 [pii]
PST - ppublish
SO  - Adv Anat Pathol. 2017 May;24(3):151-160. doi: 10.1097/PAP.0000000000000150.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>